𝛼SK or Searchbullish
IPO Databook: NeuroSpectrum Insights (NSIH US) - Jul 2026
113 Views16 Jul 2026 10:28
SUMMARY
- NeuroSpectrum Insights is a pre-revenue medical device company commercializing GyriCalc, a patented software for autism diagnosis using MRI images, targeting U.S. and Canadian markets.
- GyriCalc received FDA 510(k) marketing clearance in July 2025, demonstrating a 94% autism identification rate, with a second study initiated in July 2026.
- The company reported a net loss of $(1,826,397) in 2025 and an accumulated deficit of $(7,677,091) by March 2026, raising going concern doubts.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- IPO Databook: NeuroSpectrum Insights (NSIH US) - Jul 202616 Jul 2026
x